Back to Search Start Over

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases

Authors :
G. A. Dashyan
V. F. Semiglazov
P. V. Krivorot’ko
T. Yu. Semiglazova
E. E. Topuzov
R. M. Paltuev
K. Yu. Zernov
V. S. Apollonova
S. S. Ereshchenko
A. V. Petrova
E. K. Zhil’tsova
O. A. Ivanova
Source :
Опухоли женской репродуктивной системы, Vol 12, Iss 1, Pp 46-51 (2016)
Publication Year :
2016
Publisher :
ABV-press, 2016.

Abstract

Brain metastases are detectable in 25–35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of investigations substantiating the use of anti-HER-2 targeting agents, as well as the innovative agent T-DM1 to treat brain metastases.

Details

Language :
Russian
ISSN :
19944098 and 19998627
Volume :
12
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Опухоли женской репродуктивной системы
Publication Type :
Academic Journal
Accession number :
edsdoj.f195e60b5004d29b0a2524764f3d9a8
Document Type :
article
Full Text :
https://doi.org/10.17650/1994-4098-2016-12-1-46-51